Stryker Corporation - SYK STOCK NEWS

Stryker (NYSE:SYK) announced FDA 510(k) clearance for its Q Guidance System with Cranial Guidance Software, enhancing surgical procedures in cranial operations. The system is designed for computer-assisted planning, providing real-time guidance by tracking instruments in patient images. This innovative software is aimed at improving surgical accuracy and confidence, marking a significant advancement in cranial navigation technology. Additionally, the system supports varied surgical instruments and new workflows for brain biopsies.

President Robbie Robinson emphasized the importance of this milestone for transforming cranial surgery and reaffirmed Stryker's commitment to advanced navigation products.

Stryker (NYSE:SYK) has declared a quarterly dividend of $0.75 per share, payable on April 28, 2023, to shareholders on record as of March 31, 2023. This dividend reflects a 7.9% increase compared to the previous year, although it remains unchanged from the last quarter. As a leading medical technology company, Stryker aims to enhance healthcare outcomes globally, impacting over 130 million patients annually with its innovative medical products and services across various sectors including neurotechnology, orthopaedics, and spine.

Stryker (NYSE:SYK) reported fourth quarter 2022 net sales of $5.2 billion, a 10.7% increase, with organic growth at 13.2%. The full year net sales reached $18.4 billion, up 7.8%. However, adjusted operating income margin fell by 70 basis points to 26.6%, while reported EPS decreased 15.0% to $1.47. Despite challenges such as a $216 million goodwill impairment in its Spine business, Stryker expects organic net sales growth for 2023 between 7.0% and 8.5%. CEO Kevin Lobo anticipates continued positive momentum in sales, though acknowledges macro-economic volatility.

Stryker (NYSE:SYK) will host a conference call on January 31, 2023, at 4:30 p.m. ET to discuss its operating results for the quarter ending December 31, 2022. Final results will be available at 4:05 p.m. on the same day. Interested parties can register for the call through a provided link and are advised to register at least a day in advance or 15 minutes prior. A simultaneous webcast will also be available on the company's Investor Relations page. A replay will be accessible post-call, along with an archive of the webcast two hours after the live call ends.

Stryker (NYSE:SYK) has launched Citrefix™, a new suture anchor system designed for foot and ankle surgeries. This innovative system utilizes Citregen™, a bioresorbable material that mimics natural bone properties, promoting better healing and recovery without chronic inflammation. The Citrefix system is set to improve surgical outcomes with increased pull-out strength compared to traditional anchors. Following the successful launch of Citrelock, Citrefix is part of Stryker's expanding Citregen portfolio, with more products expected in 2023. Citregen has already received the 2022 Technology Innovation and Development Award.

Stryker (NYSE:SYK) has declared a quarterly dividend of $0.75 per share, payable on January 31, 2023, to shareholders of record as of December 30, 2022. This marks a 7.9% increase compared to previous dividends. CEO Kevin Lobo expressed confidence in the company’s growth prospects despite challenging economic conditions, highlighting the steady increase in dividends as a sign of strength. Stryker continues to impact over 100 million patients annually through its innovative medical technologies.

Stryker (NYSE:SYK) has launched the OR of the Future at its Flower Mound facility, emphasizing enhanced patient safety and operational efficiency in operating rooms. This innovative model integrates advanced technology to promote infection prevention and workflow optimization. Key features include seamless software integration, improved sterility, and modular design for future upgrades. With over 30 years of experience, Stryker aims to revolutionize OR design, ultimately improving patient care and surgical team performance. This initiative targets better healthcare outcomes, impacting over 100 million patients annually.

Stryker (NYSE: SYK) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022. Kevin Lobo, the Chair and CEO, along with Jason Beach, VP of Investor Relations, will present at 8:50 a.m. Eastern Time. A webcast and replay of the presentation will be available on Stryker's website (www.stryker.com), archived for later access.

As a leading medical technology firm, Stryker aims to enhance healthcare through innovative products in various sectors, impacting over 100 million patients globally each year.

Stryker (NYSE:SYK) reported a strong third quarter of 2022 with net sales increasing by 7.7% to $4.5 billion, driven by organic growth of 9.9%. Operating income margin was 18.0%, while reported EPS rose 87.7% to $2.14. Adjusted EPS, however, decreased by 3.6% to $2.12. The company anticipates full-year organic growth between 8.5% and 9.0%, but expects foreign currency fluctuations to negatively impact sales and adjusted EPS by $0.35 to $0.40.